Best Hospitals for Chemotherapy in Delhi NCR, India

Chemotherapy encompasses a broad class of pharmacological agents—alkylating agents, antimetabolites, topoisomerase inhibitors, antimicrotubule agents, platinum analogues, and anthracyclines—each targeting specific vulnerabilities in the cell cycle to induce apoptosis or mitotic arrest in rapidly dividing cells. The physiological impact is systemic: while malignant cells are the primary target, rapidly proliferating normal tissues (bone marrow, gastrointestinal mucosa, hair follicles, and gonads) are also affected, giving rise to the characteristic toxicity profile including myelosuppression, mucositis, nausea, alopecia, peripheral neuropathy, and cardiotoxicity with certain agents such as doxorubicin or trastuzumab. Risk is stratified using validated tools including the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI), the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH), and ECOG/Karnofsky Performance Status, which guide dose intensity and supportive care planning.

• Newly diagnosed solid tumor patients (breast, lung, colorectal, gastric, ovarian, bladder, cervical, head & neck) requiring first-line, adjuvant, or neoadjuvant systemic therapy
• Hematologic malignancy patients (lymphoma, leukemia, multiple myeloma) requiring induction, consolidation, or salvage chemotherapy
• Patients with metastatic or locally advanced disease where chemotherapy is combined with immunotherapy (checkpoint inhibitors: pembrolizumab, nivolumab, atezolizumab) or targeted agents
• Candidates for high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCT) for relapsed/refractory lymphoma or multiple myeloma
• Patients requiring intrathecal chemotherapy for CNS involvement or prophylaxis (e.g., methotrexate, cytarabine in ALL)
• +1 more

Required Pre-Treatment Diagnostics:

• PET-CT scan (18F-FDG) for staging and treatment response assessment (Deauville criteria for lymphoma; RECIST 1.1 for solid tumors)
• Biopsy with comprehensive immunohistochemistry (IHC), in-situ hybridization (FISH/ISH), and next-generation sequencing (NGS) panel for molecular profiling
• Complete blood count with differential, comprehensive metabolic panel (renal and hepatic function), serum LDH, beta-2 microglobulin, tumor markers (CEA, CA125, AFP, beta-hCG, PSA as applicable)
• Echocardiogram (ECHO) or MUGA scan (mandatory before anthracyclines; baseline LVEF must be ≥50%)
• Pulmonary function tests (PFTs) before bleomycin-containing regimens
• +6 more

Chemotherapy is not a single treatment but a spectrum of regimens, delivery routes, and combination strategies, individualized based on tumor histology, molecular subtype, stage, comorbidities, and performance status.

Standard Systemic Intravenous Chemotherapy: The foundation of most regimens. Multi-agent combinations are preferred over single agents to overcome drug resistance. Key backbone regimens include: AC-T (doxorubicin + cyclophosphamide followed by paclitaxel) for breast cancer; FOLFOX (5-fluorouracil + leucovorin + oxaliplatin) or FOLFIRI + bevacizumab/cetuximab for colorectal cancer; BEP (bleomycin + etoposide + cisplatin) for germ-cell tumors; R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) for DLBCL; ABVD (doxorubicin + bleomycin + vinblastine + dacarbazine) for Hodgkin lymphoma; and platinum doublets (carboplatin/paclitaxel ± pembrolizumab) for NSCLC. Cycles are typically administered every 2–3 weeks through a peripherally inserted central catheter (PICC line) or implantable port (Port-a-Cath), reducing venous access complications across 4–8 cycles.

Dose-Dense and Dose-Intensified Regimens: Dose-dense AC-T (every 2 weeks with G-CSF support) has demonstrated superior disease-free survival in high-risk breast cancer compared to standard 3-weekly scheduling. Escalated BEACOPP is used for advanced-stage Hodgkin lymphoma in fit patients (age <60, ECOG 0–1) where superior tumor control outweighs increased toxicity. Dose intensity is managed with prophylactic G-CSF (filgrastim, pegfilgrastim) to prevent febrile neutropenia.

High-Dose Chemotherapy with Autologous Stem Cell Transplantation (HDC-ASCT): Used in relapsed/refractory Hodgkin lymphoma (BEAM conditioning: carmustine + etoposide + cytarabine + melphalan), multiple myeloma (melphalan 200 mg/m² conditioning), and selected DLBCL. Stem cells are harvested after mobilization with G-CSF ± plerixafor, cryopreserved, and reinfused 24–72 hours after myeloablative conditioning. Leading Indian centres (Tata Memorial Hospital, Apollo, Fortis) and UAE centres (Cleveland Clinic Abu Dhabi, Burjeel) perform ASCT within dedicated BMT units with HEPA-filtered positive-pressure rooms.

Pre-Treatment Phase (Weeks 1–3 before Cycle 1): Step 1 — Remote Case Submission: Patient submits pathology reports, imaging (PET-CT, MRI, CT), operative notes, and prior treatment records to GAF Healthcare's oncology coordination team. A medical oncologist in India or the UAE performs a virtual consultation within 48–72 hours. Step 2 — Multidisciplinary Tumor Board Review: The treating centre convenes a tumor board (medical oncologist, radiation oncologist, surgical oncologist, pathologist, radiologist) to confirm diagnosis, review molecular profiling (NGS/IHC), and ratify the treatment regimen per NCCN/ESMO guidelines. Step 3 — Travel and Arrival: GAF Healthcare arranges the e-Medical visa (India) or UAE entry visa. The patient and one attendant arrive; airport transfer to accredited hospital or partner accommodation is coordinated. Step 4 — Baseline Work-Up (Day 1–3): Repeat or confirmatory imaging, blood panel, ECHO/PFTs/audiometry as required, pharmacogenomic testing, central venous access placement (PICC line or Port-a-Cath implant under local anesthesia), and a pre-chemotherapy anesthesia/cardiac risk assessment. Step 5 — Patient Education and Supportive Care Planning: Dietitian consultation (nutritional optimization, antiemetic dietary guidance), oncology nurse education on self-monitoring for fever/neutropenia, dental clearance, and fertility preservation referral if applicable.

Chemotherapy Administration (Per Cycle): Step 6 — Cycle 1 (Day 1 of Treatment): Pre-medications administered IV (antiemetics: ondansetron, dexamethasone, aprepitant for highly emetogenic regimens; antihistamines and steroids for taxane hypersensitivity prophylaxis). Chemotherapy infusion administered in a dedicated oncology day-care unit under continuous nursing monitoring. Duration ranges from 1 hour (single-agent IV push) to 48–96 hours (continuous 5-FU infusion via ambulatory pump). Vital signs, allergic reactions, and infusion-related reactions are monitored in real time. Step 7 — Nadir Period (Days 7–14): The period of maximum myelosuppression. CBC is monitored at nadir (typically Day 10–14). G-CSF support (pegfilgrastim Day 2 of each cycle) is administered for dose-dense or high-risk regimens. Patients are educated on fever protocols (any temperature ≥38.3°C requires immediate hospital presentation for febrile neutropenia assessment and empiric broad-spectrum antibiotics). Step 8 — Cycle Recovery and Re-Assessment (Day 15–21): Blood counts recover; fitness for next cycle confirmed by ANC ≥1,500/µL and platelets ≥100,000/µL. Interim imaging (CT or PET-CT) performed after cycles 2–4 to assess treatment response (RECIST 1.1 / Deauville criteria).

Multi-Cycle Regimen (Months 1–6): Step 9 — Cycles 2–8: Repeat administration per schedule (every 2 or 3 weeks). Between cycles, patients may be permitted to return home or stay in local accommodation coordinated by GAF Healthcare. GAF provides telemedicine access to the treating oncologist for symptom management and lab result review during intervals.